Macular Degeneration Global Clinical Trials Review, H1, 2012

2012-02-28
Published : Feb-2012

Macular Degeneration Global Clinical Trials Review, H1, 2012

Summary

GlobalData’s clinical trial report, “Macular Degeneration Global Clinical Trials Review, H1, 2012″ provides data on the Macular Degeneration clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Macular Degeneration. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Macular Degeneration. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

– Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
– Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
– Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

– Understand the dynamics of a particular indication in a condensed manner
– Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
– Obtain discontinued trial listing for trials across the globe
– Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Macular Degeneration Clinical Trials

Published: February 2012
No. of Pages: 127
Price: US$1000

Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 7
Introduction 8
Macular Degeneration 8
Report Guidance 8
Clinical Trials by Region 9
Clinical Trials by Country 10
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 12
Top Five Countries Contributing to Clinical Trials in Europe 13
Top Countries Contributing to Clinical Trials in North America 14
Top Countries Contributing to Clinical Trials in Middle East and Africa 15
Top Five Countries Contributing to Clinical Trials in Central and South America 16
Clinical Trials by BRIC Nations 17
Clinical Trials by G7 Nations 18
Clinical Trials in G7 Nations by Trial Status 19
Clinical Trials by E7 Nations 20
Clinical Trials in E7 Nations by Trial Status 21
Clinical Trials by Phase 22
In Progress Trials by Phase 23
Clinical Trials by Trial Status 24
Unaccomplished Trials of Macular Degeneration 25
Subjects Recruited Over a Period of Time 30
Prominent Sponsors 31
Top Companies Participating in Macular Degeneration Therapeutics Clinical Trials 33
Prominent Drug Comparison 35
Clinical Trial Profiles 36
Clinical Trial Overview of Top Companies 36
Novartis AG 36
Clinical Trial Overview of Novartis AG 36
Pfizer Inc. 39
Clinical Trial Overview of Pfizer Inc. 39
GlaxoSmithKline plc 41
Clinical Trial Overview of GlaxoSmithKline plc 41
Notal Vision Ltd. 42
Clinical Trial Overview of Notal Vision Ltd. 42
Eyetech Pharmaceuticals, Inc. 43
Clinical Trial Overview of Eyetech Pharmaceuticals, Inc. 43
Allergan, Inc. 44
Clinical Trial Overview of Allergan, Inc. 44
Regeneron Pharmaceuticals, Inc. 45
Clinical Trial Overview of Regeneron Pharmaceuticals, Inc. 45
F. Hoffmann-La Roche Ltd. 46
Clinical Trial Overview of F. Hoffmann-La Roche Ltd. 46
OPKO Health, Inc. 47
Clinical Trial Overview of OPKO Health, Inc. 47
Ophthotech Corp. 48
Clinical Trial Overview of Ophthotech Corp. 48
Alcon Research Ltd. 49
Clinical Trial Overview of Alcon Research Ltd. 49
Genaera Liquidating Trust 50
Clinical Trial Overview of Genaera Liquidating Trust 50
NeoVista, Inc. 51
Clinical Trial Overview of NeoVista, Inc. 51
Genentech, Inc. 52
Clinical Trial Overview of Genentech, Inc. 52
Advanced Cell Technology, Inc. 53
Clinical Trial Overview of Advanced Cell Technology, Inc. 53
Bayer AG 54
Clinical Trial Overview of Bayer AG 54
Lpath, Inc. 55
Clinical Trial Overview of Lpath, Inc. 55
Oraya Therapeutics, Inc. 56
Clinical Trial Overview of Oraya Therapeutics, Inc. 56
Acucela Inc. 57
Clinical Trial Overview of Acucela Inc. 57
Othera Pharmaceuticals, Inc. 58
Clinical Trial Overview of Othera Pharmaceuticals, Inc. 58
Clinical Trial Overview of Top Universities / Institutes / Hospitals 59
Medical University of Vienna 59
Clinical Trial Overview of Medical University of Vienna 59
The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery 60
Clinical Trial Overview of The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery 60
Vitreous-Retina-Macula Consultants of New York 61
Clinical Trial Overview of Vitreous-Retina-Macula Consultants of New York 61
Kyoto University 62
Clinical Trial Overview of Kyoto University 62
Johns Hopkins University 63
Clinical Trial Overview of Johns Hopkins University 63
Lawson Health Research Institute 64
Clinical Trial Overview of Lawson Health Research Institute 64
Retina Research Foundation 65
Clinical Trial Overview of Retina Research Foundation 65
Asociacion para Evitar la Ceguera en Mexico I.A.P. 66
Clinical Trial Overview of Asociacion para Evitar la Ceguera en Mexico I.A.P. 66
Manhattan Eye Ear & Throat Hospital 67
Clinical Trial Overview of Manhattan Eye Ear & Throat Hospital 67
University of California, Davis 68
Clinical Trial Overview of University of California, Davis 68
University of California, San Diego 69
Clinical Trial Overview of University of California, San Diego 69
Maastricht University Medical Center 70
Clinical Trial Overview of Maastricht University Medical Center 70
University of Pittsburgh 71
Clinical Trial Overview of University of Pittsburgh 71
University Health Network 72
Clinical Trial Overview of University Health Network 72
Assistance Publique – Hopitaux de Paris 73
Clinical Trial Overview of Assistance Publique – Hopitaux de Paris 73
University Hospital Inselspital, Berne 74
Clinical Trial Overview of University Hospital Inselspital, Berne 74
University of Sao Paulo 75
Clinical Trial Overview of University of Sao Paulo 75
Kyungpook National University 76
Clinical Trial Overview of Kyungpook National University 76
Seirei Hamamatsu General Hospital 77
Clinical Trial Overview of Seirei Hamamatsu General Hospital 77
Rudolf Foundation Clinic 78
Clinical Trial Overview of Rudolf Foundation Clinic 78
Five Key Clinical Profiles 79
Appendix 124
Abbreviations 124
Definitions 124
Research Methodology 125
Secondary Research 125
About GlobalData 126
Contact Us 126
Disclaimer 126
Source 127

List of Tables

Macular Degeneration Therapeutics Market, Global, Clinical Trials by Zone, 2012* 9
Macular Degeneration Therapeutics Market, Global, Clinical Trials by Top Countries, 2012* 10
Macular Degeneration Therapeutics Market, Global, Clinical Trials In Progress by Top Countries, 2012* 11
Macular Degeneration Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2012* 12
Macular Degeneration Therapeutics Clinical Trials, Europe, Top Five Countries, 2012* 13
Macular Degeneration Therapeutics Clinical Trials, North America, Top Countries, 2012* 14
Macular Degeneration Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2012* 15
Macular Degeneration Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2012* 16
Macular Degeneration Therapeutics Clinical Trials, BRIC Countries, 2012* 17
Macular Degeneration Therapeutics Clinical Trials, G7 Countries, 2012* 18
Macular Degeneration Therapeutics Market, G7 Countries, Clinical Trials by Trial Status, 2012* 19
Macular Degeneration Therapeutics Clinical Trials, E7 Countries, 2012* 20
Macular Degeneration Therapeutics Market, E7 Countries, Clinical Trials by Trial Status, 2012* 21
Macular Degeneration Therapeutics Market, Global, Clinical Trials by Phase, 2012* 22
Macular Degeneration Therapeutics Market, Global, Clinical Trials In Progress by Phase 2012* 23
Macular Degeneration Therapeutics Market, Global, Clinical Trials by Trial Status, 2012* 24
Macular Degeneration Therapeutics Market, Global, Suspended Clinical Trials, 2012* 25
Macular Degeneration Therapeutics Market, Global, Withdrawn Clinical Trials, 2012* 26
Macular Degeneration Therapeutics Market, Global, Terminated Clinical Trials, 2012* 27
Macular Degeneration Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2005-2010 30
Macular Degeneration Therapeutics Clinical Trials, Global, Key Sponsors, 2012* 32
Macular Degeneration Therapeutics Clinical Trials, Global, Top Companies by Phase, 2012* 34
Macular Degeneration Therapeutics Clinical Trials, Global, Clinical Trials by Prominent Drugs, 2012* 35
Macular Degeneration Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2012* 36
Macular Degeneration Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2012* 39
Macular Degeneration Therapeutics Clinical Trials Market, Global, Clinical Trials by GlaxoSmithKline plc, 2012* 41
Macular Degeneration Therapeutics Clinical Trials Market, Global, Clinical Trials by Notal Vision Ltd., 2012* 42
Macular Degeneration Therapeutics Clinical Trials Market, Global, Clinical Trials by Eyetech Pharmaceuticals, Inc., 2012* 43
Macular Degeneration Therapeutics Clinical Trials Market, Global, Clinical Trials by Allergan, Inc., 2012* 44
Macular Degeneration Therapeutics Clinical Trials Market, Global, Clinical Trials by Regeneron Pharmaceuticals, Inc., 2012* 45
Macular Degeneration Therapeutics Clinical Trials Market, Global, Clinical Trials by F. Hoffmann-La Roche Ltd., 2012* 46
Macular Degeneration Therapeutics Clinical Trials Market, Global, Clinical Trials by OPKO Health, Inc., 2012* 47
Macular Degeneration Therapeutics Clinical Trials Market, Global, Clinical Trials by Ophthotech Corp., 2012* 48
Macular Degeneration Therapeutics Clinical Trials Market, Global, Clinical Trials by Alcon Research Ltd., 2012* 49
Macular Degeneration Therapeutics Clinical Trials Market, Global, Clinical Trials by Genaera Liquidating Trust, 2012* 50
Macular Degeneration Therapeutics Clinical Trials Market, Global, Clinical Trials by NeoVista, Inc., 2012* 51
Macular Degeneration Therapeutics Clinical Trials Market, Global, Clinical Trials by Genentech, Inc., 2012* 52
Macular Degeneration Therapeutics Clinical Trials Market, Global, Clinical Trials by Advanced Cell Technology, Inc., 2012* 53
Macular Degeneration Therapeutics Clinical Trials Market, Global, Clinical Trials by Bayer AG, 2012* 54
Macular Degeneration Therapeutics Clinical Trials Market, Global, Clinical Trials by Lpath, Inc., 2012* 55
Macular Degeneration Therapeutics Clinical Trials Market, Global, Clinical Trials by Oraya Therapeutics, Inc., 2012* 56
Macular Degeneration Therapeutics Clinical Trials Market, Global, Clinical Trials by Acucela Inc., 2012* 57
Macular Degeneration Therapeutics Clinical Trials Market, Global, Clinical Trials by Othera Pharmaceuticals, Inc., 2012* 58
Macular Degeneration Therapeutics Clinical Trials Market, Global, Clinical Trials by Medical University of Vienna, 2012* 59
Macular Degeneration Therapeutics Clinical Trials Market, Global, Clinical Trials by The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery, 2012* 60
Macular Degeneration Therapeutics Clinical Trials Market, Global, Clinical Trials by Vitreous-Retina-Macula Consultants of New York, 2012* 61
Macular Degeneration Therapeutics Clinical Trials Market, Global, Clinical Trials by Kyoto University, 2012* 62
Macular Degeneration Therapeutics Clinical Trials Market, Global, Clinical Trials by Johns Hopkins University, 2012* 63
Macular Degeneration Therapeutics Clinical Trials Market, Global, Clinical Trials by Lawson Health Research Institute, 2012* 64
Macular Degeneration Therapeutics Clinical Trials Market, Global, Clinical Trials by Retina Research Foundation, 2012* 65
Macular Degeneration Therapeutics Clinical Trials Market, Global, Clinical Trials by Asociacion para Evitar la Ceguera en Mexico I.A.P., 2012* 66
Macular Degeneration Therapeutics Clinical Trials Market, Global, Clinical Trials by Manhattan Eye Ear & Throat Hospital, 2012* 67
Macular Degeneration Therapeutics Clinical Trials Market, Global, Clinical Trials by University of California, Davis, 2012* 68
Macular Degeneration Therapeutics Clinical Trials Market, Global, Clinical Trials by University of California, San Diego, 2012* 69
Macular Degeneration Therapeutics Clinical Trials Market, Global, Clinical Trials by Maastricht University Medical Center, 2012* 70
Macular Degeneration Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Pittsburgh, 2012* 71
Macular Degeneration Therapeutics Clinical Trials Market, Global, Clinical Trials by University Health Network, 2012* 72
Macular Degeneration Therapeutics Clinical Trials Market, Global, Clinical Trials by Assistance Publique – Hopitaux de Paris, 2012* 73
Macular Degeneration Therapeutics Clinical Trials Market, Global, Clinical Trials by University Hospital Inselspital, Berne, 2012* 74
Macular Degeneration Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Sao Paulo, 2012* 75
Macular Degeneration Therapeutics Clinical Trials Market, Global, Clinical Trials by Kyungpook National University, 2012* 76
Macular Degeneration Therapeutics Clinical Trials Market, Global, Clinical Trials by Seirei Hamamatsu General Hospital, 2012* 77
Macular Degeneration Therapeutics Clinical Trials Market, Global, Clinical Trials by Rudolf Foundation Clinic, 2012* 78

 

List of Figures

Macular Degeneration Therapeutics Market, Global, Clinical Trials by Zone (%), 2012* 9
Macular Degeneration Therapeutics Market, Global, Clinical Trials by Top Countries, 2012* 10
Macular Degeneration Therapeutics Market, Global, Clinical Trials In Progress by Top Countries, 2012* 11
Macular Degeneration Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2012* 12
Macular Degeneration Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2012* 13
Macular Degeneration Therapeutics Clinical Trials, North America, Top Countries (%), 2012* 14
Macular Degeneration Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2012* 15
Macular Degeneration Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2012* 16
Macular Degeneration Therapeutics Clinical Trials, BRIC Countries (%), 2012* 17
Macular Degeneration Therapeutics Clinical Trials, G7 Countries (%), 2012* 18
Macular Degeneration Therapeutics Market, G7 Countries, Clinical Trials by Trial Status, 2012* 19
Macular Degeneration Therapeutics Clinical Trials, E7 Countries (%), 2012* 20
Macular Degeneration Therapeutics Market, E7 Countries, Clinical Trials by Trial Status, 2012* 21
Macular Degeneration Therapeutics Market, Global, Clinical Trials by Phase (%), 2012* 22
Macular Degeneration Therapeutics Market, Global, Clinical Trials In Progress by Phase, 2012* 23
Macular Degeneration Therapeutics Market, Global, Clinical Trials by Trial Status, 2012* 24
Macular Degeneration Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2005-2010 30
Macular Degeneration Therapeutics Clinical Trials, Global, Key Sponsors, 2012* 31
Macular Degeneration Therapeutics Clinical Trials, Global, Top Companies by Phase, 2012* 33
Macular Degeneration Therapeutics Clinical Trials, Global, Clinical Trials by Prominent Drugs, 2012* 35
GlobalData Methodology 125

 

Filed in: Pharmaceutical
Tags: 
More Reports
Title Price Buy Now

Ambulatory EHR Market by Delivery Mode (Cloud-based, On-premise), Application (e-Prescribing, PHM, Health Analytics, Practice, Patient & Referral Management), Practice Size (Large, Small-to-Medium, Solo), End User (Independent) – Global Forecast to 2027

“The ambulatory EHR market is projected to grow at a CAGR of 6.1% between 2022 and 2027.” The global ambulatory EHR market is projected to reach USD 5.7 billion in 2022 to USD 7.7 billion by 2027, at a CAGR of 6.1%during the forecast period. Growth in this market is driven by the opportunities provided by the market such as increasing demand for cloud-based ambulatory EHR market, and shift towards patient-centric healthcare delivery. However, the interoperability issues & data security concerns are some of the challenges that are expected to limit the growth of the market to a certain extent during the forecast period. “Cloud-based was the fastest-growing segment in the delivery mode of ambulatory EHR market in 2021” Cloud-based segment is projected to growth at the hi......
 $4950

Pharmaceutical Excipients Market by Product (Organic Chemicals (Carbohydrates), Inorganic Chemicals (Calcium Phosphate)), Functionality (Fillers, Binders, Lubricants, Preservatives), Formulation (Tablets, Capsules, Parenteral) – Global Forecast to 2027

“The pharmaceutical excipients market growth can be attributed to factors such as the rising pharmaceuticals market, advancements in functional excipients, and the growing generics market. The rapidly growing biopharmaceuticals sector will also influence market growth..” The pharmaceutical excipients market is projected to reach USD 11.5 Billion by 2027 from USD 8.6 Billion in 2022, at a CAGR of 5.9% during the forecast period.The growth can be attributed to the expanding pharmaceutical industry which has fueled the drug production thereby increasing consumption rate for excipients. Additionally, factors like functional excipients development and upsurge in generics market is also likely to propel market growth. “The fillers & diluents functionality accounted for the larges......
 $

Digital Pharmacy Market by Drug (Rx, OTC), Product (Medicine, Personal Care, Vitamins & Supplements, Diabetes, CVD, Oncology), Platform (Apps, Websites), Business Model (Captive, Franchise, Aggregator), Geographic (Urban, Rural) – Global Forecasts to 2027

“Digital Pharmacy market to register a CAGR of 17.0%  during the forecasts period The digital pharmacy market is expected to reach USD 211.9 billion by 2027 from USD 96.5 billion in 2022, at a CAGR of 17.0% during the forecast period. The growth of this market is driven by the growing consumer preference toward buying online medicines during and post COVID-19 pandemic, consolidation in the market and partnerships, and increasing geriatric population. However, patients relying on pharmacists for clinical support and increasing number of illegal pharmacies are expected to restrain the growth of this market during the forecast period. “Over-the-counter (OTC) products segment is estimated  to grow at the highest rate during the forecast period” On the basis  ofdrug type, t......
 $4950

Pharmacy Automation Market by Product (Automated Medication Dispensing & Storage Systems, Table-Top Counters, Retrieval Systems, Medication Compounding), End User (Inpatient, Outpatient (Fast-Track Clinics), Retail Pharmacies) – Global Forecast to 2027

The pharmacy automation market is expected to grow at a CAGR of 7.9% in the forecast period. The pharmacy automation market is projected to reach USD 8.2 billion by 2027 from USD 5.6 billion in 2022, at a CAGR of 7.9% during the forecast period. The growth in this market is attributed to the growing need to minimize medication errors, rapid decentralization of pharmacies, and growing focus on automation to reduce labor costs. However, the stringent regulations that delay product launches can inhibit the growth of this market. Based on product, the automated medication dispensing and storage systems segment holds the largest market share in 2021 Based on products, the pharmacy automation market is segmented into automated medication dispensing and storage systems, automated packagi......
 $4950

Topical Drug Delivery Market by Type (Semi-solids (Creams, Gels, Lotions), Solids(Suppositories), Liquids(Solutions), Transdermal products), Route(Dermal, Ophthalmic), Facility of Use (Homecare setting, Hospitals, Burn Centres) – Global Forecast to 2027

The topical drug delivery market is expected to grow at a CAGR of 8.9% in the forecast period. The global topical drug delivery market is projected to reach USD 317.8 billion by 2027 from USD 207.4 billion in 2022, at a CAGR of 8.9%. The growth of this market can largely be attributed to the high prevalence of topical prescription therapy for dry eye diseases,  growing focus of pharmaceutical companies on the R&D of smart transdermal drug delivery systems, increase in prevalence of central nervous disorders,  rising preference for non-invasive drug delivery methods. “The semi-solid formulation segment accounted for the largest share of the topical drug delivery market, based on  product in 2021.” Based on products, the topical drug delivery the market is segmented into ......
 $4950

Cognition and Memory Enhancement Market by Product & Service (Cognition & Memory-enhancing Drugs, Brain-boosting Nutraceuticals, Cognitive Assessment & Training Solutions), Region (North America, Europe, Asia Pacific, ROW) – Global Forecast to 2026

“Increasing incidence and prevalence of neurological disorders is a key factors driving growth in the cognition and memory enhancement market’’ The global cognition and memory enhancement market is projected to reach USD 38.9 billion by 2026 from USD 23.4 billion in 2021, at a CAGR of 10.7% during the forecast period. Elevating prevalence of neurological disorders, such as dementia, epilepsy, Parkinson’s disease, Huntington’s disease, headache disorders, multiple sclerosis, neuroinfections, stroke, and cerebral palsy, have increased significantly over the years. “By product & service segment, the cognition & memory-enhancing drugs segment has registered fastest growth rate during the forecast period” Based on product & service, the cognition and memory en......
 $4950

High Potency APIs/HPAPI Market by Type (Innovative, Generic), Type of Synthesis (Synthetic, Biotech, Biosimilars, mAbs, Vaccines), Manufacturers (Captive, Merchant), Application (Oncology, Hormonal Imbalance, Glaucoma) Region – Global forecast to 2027

The HPAPI market is projected to reach USD 39.6 Billion by 2027 from USD 24.5 billion in 2022, at a CAGR of 10.1% from 2022 to 2027. The market is driven by increasing demand for oncology drugs, growing demand for antibody-drug conjugates and others. “The innovative HPAPIs segment is expected to account for the largest share of the market in 2021” Based on type, the HPAPI market is segmented into innovative and generic. The innovative segment is expected to account for the largest share of the HPAPI market in 2021. The large share can be attributed to the increased R&D investments. “The Synthetic APIs segment to account for the largest share of the market in 2021” Based on type of synthesis, the market is segmented into synthetic and biotech HPAPIs. The synthetic AP......
 $4950

Plasma Fractionation Market by Product (Immunoglobulins, Albumin, Protease Inhibitors, von Willebrand Factor, PCC), Application (Neurology, Immunology, Hematology, Rheumatology), End User (Clinical Research, Hospitals & Clinics) – Global Forecast to 2027

“Increased risk of communicable diseases, Rising prevalence of bleeding disorders in global population, Use of Immunoglobulin’s for a range of neurological conditions, including multiple sclerosis, neuropathic pain, and chronic fatigue syndrome is expected to drive the overall growth of the plasma fractionation market.” The global plasma fractionation market size is projected to reach USD 36.7 billion by 2027 from USD 26.5 billion in 2022, at a CAGR of 6.7% during the forecast period. Market growth is driven mainly by factors such as rapid growth of geriatric population, growing prevalence of respiratory disorders such as alpha-1-antitrypsin deficiency (AATD) and emphysema, and use of plasma fractionation products as first-line therapies for a number of bleeding, hematological, an......
 $4950

Patient Engagement Solutions Market by Component (Software, Services), Delivery (On-Premise, Cloud), Therapy Area (CVD, Diabetes, Obesity, Fitness), Functionality (E-prescribing, Virtual care), End User (Provider, Payer, Patients) – Global Forecast to 2027

“Patient engagement solutions market to register a CAGR of 10.0% from 2022 to 2027” The patient engagement solutions market is projected to reach USD 27.9 billion by 2027 from USD 17.3 billion in 2022, at a CAGR of 10.0% during the forecast period. The growth of this market is driven by the adoption and changes in government regulations to promote patient-centric care and involve patients throughout the care journey, high demand for patient engagement solutions, and the growing utilization of m- health apps. However, interoperability issues for patient engagement solutions and a dreadth of skilled IT professionals in the healthcare industry are expected to restrain the growth of this market during the forecast period. “Services segment is expected to grow at the highest rate......
 $4950

Healthcare Cloud Computing Market by Product (EMR/EHR, VNA, RIS, LIS, PIS), Deployment (Private Cloud, Hybrid Cloud, Public Cloud), Component (Software, Services), Pricing (Spot Pricing), Service (SaaS, IaaS, PaaS), End User – Global Forecasts to 2027

The global Healthcare cloud computing market is projected to reach USD 89.4  billion by 2027 from USD 39.4 billion in 2022, at a CAGR of 17.8%. The factors driving the market are adoption of technologies like telehealth, EHR, big data analytics, IoT, cloud computing, m health, wearlable devices, etc. “The healthcare provider solution was the largest segment in the healthcare cloud computing market in 2021.” The healthcare provider segment accounted for the larger share of 79.2% of the healthcare cloud computing market in 2021. The growing adoption of various health IT solutions such as EHR, e-prescribing, telehealth, mHealth, and others due to COVID-19 is one of the key factors contributing to the growth of this segment. “Among end users, the healthcare providers segment ac......
 $4950
We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy